GMED Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Globus Medical is a good buy for a beginner long-term investor with $50,000-$100,000 available, and I would rate it as a buy right now. The stock has supportive analyst coverage, strong recent earnings commentary, constructive technical momentum, and a favorable options sentiment backdrop. The lack of a strong short-term trading signal means this is not a high-conviction momentum chase, but for a long-term buyer who wants to enter now rather than wait, the setup is attractive.
GMED closed at 80.52, essentially flat on the day and just above its pivot level of 80.195. MACD histogram is positive at 0.333 and expanding, which supports improving momentum. RSI_6 at 49.319 is neutral, so the stock is not overbought and still has room to move higher. Moving averages are converging, suggesting a transition phase rather than a strong downtrend. Near-term resistance sits at 82.396 and 83.755, while support is at 77.995 and 76.636. Overall, the technical setup is mildly bullish with a stable entry area near current levels.
["Needham raised its price target to $117 and kept a Buy rating.", "Wells Fargo keeps an Overweight rating and said Q1 sales and EPS came in well ahead of estimates and consensus.", "Analysts continue to view the company favorably overall, with multiple positive ratings in recent months.", "Options flow is mildly bullish, with call interest exceeding put interest.", "News highlights strong revenue growth for Globus Medical versus peers, reinforcing the growth story.", "Technical momentum is improving, with a positive MACD histogram and price holding near pivot support."]
["Insiders have been selling, and selling has increased 389.20% over the last month.", "Hedge funds are neutral with no significant buying trend over the last quarter.", "RSI is neutral, so the stock is not showing a strong immediate breakout signal.", "No strong AI Stock Picker or SwingMax signal is present today.", "Financial snapshot data is unavailable, limiting confirmation of the latest quarter beyond analyst commentary."]
The latest quarter appears to have been strong based on analyst commentary: Wells Fargo noted that Globus Medical reported Q1 sales and EPS well ahead of estimates and consensus. The news context also points to strong revenue growth, with Globus Medical cited at 30.3% revenue growth in a comparison discussion. Since the financial snapshot was unavailable, the clearest read is that the latest quarter season was a positive one with growth momentum intact.
Analyst sentiment is positive overall. Needham raised its target to $117 from $114 and kept a Buy rating on 2026-05-08. Wells Fargo lowered its target slightly to $103 from $104 but maintained Overweight, and explicitly said Q1 results were well ahead of expectations. Earlier on 2026-03-18, Wells Fargo initiated coverage with Overweight and a $104 target. The Wall Street pros view is constructive: multiple bullish ratings and rising targets outweigh the mild target cut. The main con is that targets cluster well above the current price, but the rating trend remains favorable.
